Who are Rebamipide 2% ophthalmic solution's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Rebamipide and Esomeprazole, Bismuth Potassium Citrate, Non-PPI (Gefarnate), Rebamipide and Omeprazole.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rebamipide-2-ophthalmic-solution.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Rebamipide 2% ophthalmic solution — Competitive Intelligence Brief

Rebamipide 2% ophthalmic solution (Rebamipide 2% ophthalmic solution) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Mucoprotective agent. Area: Ophthalmology.

marketed Mucoprotective agent Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Rebamipide 2% ophthalmic solution (Rebamipide 2% ophthalmic solution) — Samsung Medical Center. Rebamipide promotes ocular surface healing and reduces inflammation by stimulating mucin secretion and protecting epithelial cells.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Rebamipide 2% ophthalmic solution TARGET	Rebamipide 2% ophthalmic solution	Samsung Medical Center	marketed	Mucoprotective agent
Rebamipide and Esomeprazole	Rebamipide and Esomeprazole	Otsuka Pharmaceutical, Inc., Philippines	marketed	Mucoprotective agent + Proton pump inhibitor combination	Rebamipide: gastric mucosa protective mechanisms; Esomeprazole: H+/K+-ATPase
Bismuth Potassium Citrate	Bismuth Potassium Citrate	Shanghai Jiao Tong University School of Medicine	marketed	Bismuth salt / mucoprotective agent	Helicobacter pylori (bacterial target); gastric mucosa (protective mechanism)
Non-PPI (Gefarnate)	Non-PPI (Gefarnate)	Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan	phase 3	Mucoprotective agent
Rebamipide and Omeprazole	Rebamipide and Omeprazole	Otsuka Pakistan Limited	phase 3	Mucoprotective agent + Proton pump inhibitor combination	Rebamipide: gastric mucosa protective pathways; Omeprazole: H+/K+-ATPase (proton pump)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Mucoprotective agent class)

Samsung Medical Center · 1 drug in this class
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rebamipide 2% ophthalmic solution — Competitive Intelligence Brief. https://druglandscape.com/ci/rebamipide-2-ophthalmic-solution. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab